Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales @ radiantinsights. com Web: http:// www. radiantinsights. com /
Frontier Pharma-Type 2 Diabetes Mellitus Market Research Report 2020
Frontier Pharma: Type 2 Diabetes Mellitus- GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects
Browse Full Research Report @: http:// www. radiantinsights. com / research / frontier-pharmatype-2-diabetes-mellitus-gpcrs-and-protein-kinases-dominate-pipeline
Summary:
‣ Type 2 diabetes mellitus( T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia( high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases.
‣ Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has resulted in a large and competitive market landscape, with a number of drugs competing with one another for different market segments, across multiple lines of therapy.
‣ The emergence over the past decade of glucagon-like peptide-1( GLP-1) receptor agonists, dipeptidyl peptidase 4( DPP-4) inhibitors and sodium-glucose cotransporter 2( SGLT-2) inhibitors has intensified competition. These new drug classes have been highly commercially successful and are now well established within the treatment algorithm.
‣ In spite of these developments, there are still significant unmet needs for T2DM, and the rationale for investment in first-in-class innovation remains strong. First-in-class products account for a considerable proportion of the large T2DM pipeline, with a diverse range of first-in-class targets identified.
https:// www. facebook. com / RadiantInsights
https:// www. linkedin. com / company / radiant-insights https:// twitter. com / radiantinsights
https:// plus. google. com /+ Radiantinsights